Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details rather than financial performance metrics.
Material Changes
On October 2, 2015, GSK reported that specific directors and connected persons acquired Ordinary Shares following the re-investment of the dividend paid on October 1, 2015. The acquisition price was 1285.97 pence per Share.
- Sir Andrew Witty (Director): Acquired 7,545 Ordinary Shares.
- Lady C Witty (Connected person of Sir Andrew Witty): Acquired 2,364 Ordinary Shares.
- Mr I W Whyte (Connected person of Mrs V A Whyte): Acquired 420 Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider share transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by directors and connected persons during the dividend reinvestment period.
- Confirm the share price of 1285.97 pence per Share at the time of the October 1, 2015 dividend reinvestment.
- Review the full list of connected persons to ensure all relevant transactions are disclosed.